Bunnage Mark E. 4

What Happened
Mark E. Bunnage, Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals (VRTX), disposed of a total of 3,148 shares in two transactions. On 2026-02-10, 1,127 shares were surrendered at $468.41 per share (transaction code F) for $527,898 — reported as payment of exercise price or tax liability. On 2026-02-11, 2,021 shares were sold in the open market at $460.43 per share for $930,529. Combined proceeds across both transactions were about $1.46 million. These were sales (not purchases), so they are routine insider dispositions rather than new insider buying.

Key Details

• Transaction dates and prices:
  • 2026-02-10: 1,127 shares @ $468.41 each = $527,898 (code F: payment of exercise price/tax withholding)
  • 2026-02-11: 2,021 shares @ $460.43 each = $930,529 (code S: open market sale)
• Total shares sold: 3,148; total reported proceeds ≈ $1,458,427.
• Footnote: F1 — the 2/10 transaction was made pursuant to Dr. Bunnage’s company‑approved Rule 10b5-1 trading plan entered 11/26/2025.
• Shares owned after the transactions: not disclosed in the filing.
• Filing date: 2026-02-12 for transactions on 2026-02-10 and 2026-02-11 — filing appears timely (no late filing indicated).

Context

• Code F typically means shares were surrendered to satisfy tax withholding or to pay an exercise price (commonly associated with option exercises or vested awards). This is often a mechanical tax/payment step rather than an active trading decision.
• The 10b5-1 plan note indicates at least one disposition was executed under a pre-established trading plan, which allows scheduled trades even when the insider may possess material nonpublic information.
• Sales by executives are common and do not by themselves indicate a change in company fundamentals; purchases would be a stronger signal of insider confidence.